© 2004 by European Society of Cardiology
Copyright © 2004, European Society of Cardiology
Therapeutic opportunities for cell cycle re-entry and cardiac regeneration
The Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, and the Department of Physiology, Faculty of Medicine, University of Manitoba, Rm. 3016, 351 Taché Avenue, Winnipeg, Manitoba, R2H 2A6, Canada
* Corresponding author. Tel.: +1 204 235 3661; fax: +1 204 233 6723. Email address: lorrie{at}sbrc.ca
Over the last two decades, considerable effort has been made to better understand putative regulators and molecular switches that govern the cell cycle in attempts to reactivate cell cycle progression of cardiac muscle. Rapid advancements on the field of stem cycle biology including evidence of cardiac progenitors within the adult myocardium itself and reports of cardiomyocyte DNA synthesis, which each suggest that the adult myocardium may in fact have the capacity for de novo myocyte regeneration. Augmenting cardiomyocyte number by targeting specific cell cycle regulatory genes or by stimulating cardiac progenitor cells to differentiate into cardiac muscle may be of therapeutic value in repopulating the adult myocardium with functionally active cells in patients with end-stage heart failure. Advancements in the area of cardiomyocyte cell cycle control and regeneration and their therapeutic potential are discussed.
KEYWORDS Cell cycle; DNA synthesis; Ventricular myocytes; Regeneration
Time for primary review 20 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. Gabel, C. Klopsch, D. Furlani, C. Yerebakan, W. Li, M. Ugurlucan, N. Ma, and G. Steinhoff Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats Interactive CardioVascular and Thoracic Surgery, July 1, 2009; 9(1): 20 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tamamori-Adachi, H. Takagi, K. Hashimoto, K. Goto, T. Hidaka, U. Koshimizu, K. Yamada, I. Goto, Y. Maejima, M. Isobe, et al. Cardiomyocyte proliferation and protection against post-myocardial infarction heart failure by cyclin D1 and Skp2 ubiquitin ligase Cardiovasc Res, November 1, 2008; 80(2): 181 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. J. Woo, C. M. Panlilio, R. K. Cheng, G. P. Liao, E. E. Suarez, P. Atluri, and H. W. Chaudhry Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2 J. Thorac. Cardiovasc. Surg., April 1, 2007; 133(4): 927 - 933. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. J. Woo, C. M. Panlilio, R. K. Cheng, G. P. Liao, P. Atluri, V. M. Hsu, J. E. Cohen, and H. W. Chaudhry Therapeutic Delivery of Cyclin A2 Induces Myocardial Regeneration and Enhances Cardiac Function in Ischemic Heart Failure Circulation, July 4, 2006; 114(1_suppl): I-206 - I-213. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Hanft, I. N. Rybakova, J. R. Patel, J. A. Rafael-Fortney, and J. M. Ervasti Cytoplasmic {gamma}-actin contributes to a compensatory remodeling response in dystrophin-deficient muscle PNAS, April 4, 2006; 103(14): 5385 - 5390. [Abstract] [Full Text] [PDF] |
||||




